Subject(s)
Humans , Female , Adult , Middle Aged , Mite Infestations/diagnosis , Dermatitis/parasitology , Dermatitis/diagnosis , Diagnosis, DifferentialABSTRACT
In patients who develop sepsis, whether due to primary, secondary or metastatic lesions, the skin is frequently affected. However, there are unresolved aspects regarding the general clinical manifestations in the skin or the prognosis and/or therapeutic implications. The main challenge in the approach to sepsis is its early diagnosis and management. In this review, we address the sepsis-skin relationship and the potential impact of early dermatological intervention on the septic patient through ten basic questions. We found little evidence of the participation of the dermatologist in sepsis alert programs. There are early skin changes that may alert clinicians on a possible sepsis, such as skin mottling or variations in acral skin temperature. In addition, the skin is an accessible and highly cost-effective tissue for etiological studies of some forms of sepsis (e.g., meningococcal purpura) and its involvement defines the prognosis of certain patients (e.g., infective endocarditis).
Subject(s)
Dermatology , Endocarditis, Bacterial , Endocarditis , Sepsis , Humans , Sepsis/diagnosis , SkinSubject(s)
Antiviral Agents/adverse effects , Coronavirus Infections/drug therapy , Drug-Related Side Effects and Adverse Reactions/epidemiology , Eosinophilia/chemically induced , Exanthema/chemically induced , Pneumonia, Viral/drug therapy , Virus Diseases/drug therapy , Adrenal Cortex Hormones/therapeutic use , Aged , Antiviral Agents/administration & dosage , COVID-19 , Cohort Studies , Coronavirus Infections/diagnosis , Coronavirus Infections/epidemiology , Disease Progression , Drug-Related Side Effects and Adverse Reactions/drug therapy , Drug-Related Side Effects and Adverse Reactions/etiology , Eosinophilia/pathology , Exanthema/drug therapy , Exanthema/pathology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pandemics , Pneumonia, Viral/diagnosis , Pneumonia, Viral/epidemiology , Retrospective Studies , Risk Assessment , Role , Virus Diseases/pathologySubject(s)
Facial Neoplasms/pathology , Lymphoma, B-Cell/pathology , Skin Neoplasms/pathology , Adult , Female , HumansABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Larva Migrans/diagnosis , Occupational Diseases/diagnosis , Gardening , Larva Migrans/pathology , Occupational Diseases/pathology , SpainABSTRACT
INTRODUCCIÓN: La hiperhidrosis (HH) es una condición muy prevalente que supone una repercusión importante en la calidad de vida. Entre las opciones terapéuticas disponibles, la oxibutinina oral consigue buenas tasas de respuesta aunque con frecuentes efectos secundarios que condicionan en muchas ocasiones el abandono del tratamiento. Tras la comercialización en nuestro país de la oxibutinina en presentación transdérmica, realizamos un estudio preliminar para valorar el control de la HH y el perfil de efectos secundarios de este tratamiento. MATERIAL Y MÉTODOS: Se realizó un estudio prospectivo con 25 pacientes que recibieron tratamiento con 2 parches semanales de oxibutinina transdérmica durante 10 semanas. La respuesta terapéutica se valoró mediante 2 escalas subjetivas: Hyperhidrosis Disease Severity Scale (HDSS) y escala analógica visual (EAV). RESULTADOS: Un 60% de los pacientes consiguieron una reducción en la puntuación de la HDSS. Todos los casos obtuvieron una disminución en la puntuación de la EAV, siendo esta de 3 puntos o superior en el 68% de los pacientes. Solo 2 pacientes (8%) presentaron efectos adversos relacionados con el tratamiento, en ambos casos en forma de dermatitis irritativa en la zona de aplicación del parche. CONCLUSIONES: Aunque se trata de una experiencia limitada, los resultados de nuestro estudio sugieren que la oxibutinina transdérmica podría tener utilidad en el manejo de la HH, con un excelente perfil de seguridad y tolerancia
BACKGROUND AND OBJECTIVE: Hyperhidrosis is very common and has a considerable impact on patients' quality of life. While oral oxybutynin is associated with good response rates, adverse effects are common and frequently cause patients to stop treatment. Following the recent launch of oxybutynin in a transdermal patch formulation in Spain, we undertook a preliminary study to assess treatment response and adverse effects in patients with hyperhidrosis. MATERIAL AND METHODS: This prospective study of 25 patients treated twice weekly with transdermal oxybutynin patches over 10 weeks assessed treatment response on 2 subjective scales: the Hyperhidrosis Disease Severity Scale (HDSS) and a visual analog scale (VAS) for sweating. RESULTS: Sixty percent of patients showed an improvement in HDSS scores. VAS scores improved in all cases, and 68% of patients achieved a reduction of 3 points or more. Just 2 patients (8%) experienced treatment-related adverse effects (irritant dermatitis at the patch application site in both cases). CONCLUSIONS: Although our results are based on a small sample, they suggest that transdermal oxybutynin could be a useful option for the treatment of hyperhidrosis and that it has an excellent safety and tolerability profile
Subject(s)
Humans , Male , Female , Adult , Hyperhidrosis/diagnosis , Hyperhidrosis/drug therapy , Administration, Cutaneous , Transdermal Patch , Dermatitis, Irritant/complications , Dermatitis, Irritant/drug therapy , Quality of Life , Drug-Related Side Effects and Adverse Reactions/complications , Prospective StudiesABSTRACT
BACKGROUND AND OBJECTIVE: Hyperhidrosis is very common and has a considerable impact on patients' quality of life. While oral oxybutynin is associated with good response rates, adverse effects are common and frequently cause patients to stop treatment. Following the recent launch of oxybutynin in a transdermal patch formulation in Spain, we undertook a preliminary study to assess treatment response and adverse effects in patients with hyperhidrosis. MATERIAL AND METHODS: This prospective study of 25 patients treated twice weekly with transdermal oxybutynin patches over 10 weeks assessed treatment response on 2 subjective scales: the Hyperhidrosis Disease Severity Scale (HDSS) and a visual analog scale (VAS) for sweating. RESULTS: Sixty percent of patients showed an improvement in HDSS scores. VAS scores improved in all cases, and 68% of patients achieved a reduction of 3 points or more. Just 2 patients (8%) experienced treatment-related adverse effects (irritant dermatitis at the patch application site in both cases). CONCLUSIONS: Although our results are based on a small sample, they suggest that transdermal oxybutynin could be a useful option for the treatment of hyperhidrosis and that it has an excellent safety and tolerability profile.